Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jordan S Fridman

Showing results (11-20 of 31) with videos related to

Pageof 4
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|May 3, 2006
Loss of p53 impedes the antileukemic response to BCR-ABL inhibitionHans-Guido Wendel, Elisa de Stanchina, Enriqué Cepero, et al.
Neoplasia (New York, N.Y.)|January 15, 2010
INCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell supportJun Li, Margaret Favata, Jennifer A Kelley, et al.
Molecular Cancer Therapeutics|February 4, 2010
Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumorsHolly K Koblish, Michael J Hansbury, Kevin J Bowman, et al.
Molecular Cancer Therapeutics|January 14, 2009
Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivoRenate Burger, Steven Le Gouill, Yu-Tzu Tai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2007
Selective inhibition of ADAM metalloproteases as a novel approach for modulating ErbB pathways in cancerJordan S Fridman, Eian Caulder, Michael Hansbury, et al.
Bioorganic & Medicinal Chemistry Letters|December 11, 2007
Conversion of an MMP-potent scaffold to an MMP-selective HER-2 sheddase inhibitor via scaffold hybridization and subtle P1' permutationsDavid M Burns, Chunhong He, Yanlong Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 16, 2011
A novel kinase inhibitor, INCB28060, blocks c-MET-dependent signaling, neoplastic activities, and cross-talk with EGFR and HER-3Xiangdong Liu, Qian Wang, Gengjie Yang, et al.
Bioorganic & Medicinal Chemistry Letters|May 22, 2009
Compelling P1 substituent affect on metalloprotease binding profile enables the design of a novel cyclohexyl core scaffold with excellent MMP selectivity and HER-2 sheddase inhibitionDavid M Burns, Yun-Long Li, Eric Shi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 6, 2009
Combined inhibition of Janus kinase 1/2 for the treatment of JAK2V617F-driven neoplasms: selective effects on mutant cells and improvements in measures of disease severityPhillip C C Liu, Eian Caulder, Jun Li, et al.
The Journal of Investigative Dermatology|June 17, 2011
Preclinical evaluation of local JAK1 and JAK2 inhibition in cutaneous inflammationJordan S Fridman, Peggy A Scherle, Robert Collins, et al.
Pageof 4

Showing results (11-20 of 31) with videos related to

Sort By:
Pageof 4
Proceedings of the National Academy of Sciences of the United States of America|May 3, 2006
Loss of p53 impedes the antileukemic response to BCR-ABL inhibitionHans-Guido Wendel, Elisa de Stanchina, Enriqué Cepero, et al.
Neoplasia (New York, N.Y.)|January 15, 2010
INCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell supportJun Li, Margaret Favata, Jennifer A Kelley, et al.
Molecular Cancer Therapeutics|February 4, 2010
Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumorsHolly K Koblish, Michael J Hansbury, Kevin J Bowman, et al.
Molecular Cancer Therapeutics|January 14, 2009
Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivoRenate Burger, Steven Le Gouill, Yu-Tzu Tai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2007
Selective inhibition of ADAM metalloproteases as a novel approach for modulating ErbB pathways in cancerJordan S Fridman, Eian Caulder, Michael Hansbury, et al.
Bioorganic & Medicinal Chemistry Letters|December 11, 2007
Conversion of an MMP-potent scaffold to an MMP-selective HER-2 sheddase inhibitor via scaffold hybridization and subtle P1' permutationsDavid M Burns, Chunhong He, Yanlong Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 16, 2011
A novel kinase inhibitor, INCB28060, blocks c-MET-dependent signaling, neoplastic activities, and cross-talk with EGFR and HER-3Xiangdong Liu, Qian Wang, Gengjie Yang, et al.
Bioorganic & Medicinal Chemistry Letters|May 22, 2009
Compelling P1 substituent affect on metalloprotease binding profile enables the design of a novel cyclohexyl core scaffold with excellent MMP selectivity and HER-2 sheddase inhibitionDavid M Burns, Yun-Long Li, Eric Shi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 6, 2009
Combined inhibition of Janus kinase 1/2 for the treatment of JAK2V617F-driven neoplasms: selective effects on mutant cells and improvements in measures of disease severityPhillip C C Liu, Eian Caulder, Jun Li, et al.
The Journal of Investigative Dermatology|June 17, 2011
Preclinical evaluation of local JAK1 and JAK2 inhibition in cutaneous inflammationJordan S Fridman, Peggy A Scherle, Robert Collins, et al.
Pageof 4